Cambridge Investment Research Advisors, Inc. Repligen Corp Transaction History
Cambridge Investment Research Advisors, Inc.
- $27.1 Billion
- Q2 2024
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Repligen Corp stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 2,115 shares of RGEN stock, worth $302,931. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,115
Previous 2,212
4.39%
Holding current value
$302,931
Previous $407,000
34.4%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding RGEN
# of Institutions
495Shares Held
53.9MCall Options Held
420KPut Options Held
85.3K-
Black Rock Inc. New York, NY7.57MShares$1.08 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.07MShares$726 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.61MShares$660 Million0.07% of portfolio
-
State Street Corp Boston, MA1.74MShares$249 Million0.01% of portfolio
-
Sands Capital Management, LLC Arlington, VA1.42MShares$204 Million0.55% of portfolio
About REPLIGEN CORP
- Ticker RGEN
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Shares Outstandng 55,491,200
- Market Cap $7.95B
- Description
- Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....